Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients

Transplantation

Volumn 84, Issue 4, 2007, Pages 467-474

  Raichlin, Eugenia ^a   Khalpey, Zain ^a,b   Kremers, Walter ^a   Frantz, Robert P ^a   Rodeheffer, Richard J ^a   Clavell, Alfredo L ^a   Edwards, Brooks S ^a   Kushwaha, Sudhir S ^a  

^a MAYO CLINIC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Calcineurin inhibitor; Cardiac transplantation; Renal function; Sirolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; URIC ACID;

ADULT; AGED; APHTHOUS ULCER; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; DIARRHEA; DISCOMFORT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; GLOMERULUS FILTRATION RATE; GREASY SKIN; HEART DISEASE; HEART TRANSPLANTATION; HICCUP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH ULCER; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; URIC ACID BLOOD LEVEL;

ADULT; AGED; CALCINEURIN; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; SIROLIMUS; TREATMENT OUTCOME; URIC ACID;

EID: 34548182861     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000276959.56959.69     Document Type: Article

References (52)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
2. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-second official adult heart transplant report-2005. J Heart Lung Transplant 2005; 24: 945.
3. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006; 25: 869.
4. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30: 964.
5. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 1991; 2: S45.
6. Andoh TF, Burdmann EA, Fransechini N, et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50: 1110.
7. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: Experimental and clinical observations. Semin Nephrol 1997; 17: 34.
8. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34: 515.
9. Banner NR, Yacoub MH. Cyclosporine in thoracic organ transplantation. Transplant Proc 2004; 36: 302S.
10. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727.
11. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
12. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
13. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
14. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 2694.
15. Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005; 24: 2129.
16. Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997; 30: 646.
17. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitorinduced nephrotoxicity. Transplantation 2000; 69: SS11.
18. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540.
19. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48.
20. Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262.
21. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16: 121.
22. Andoh TF, Lindsley J, Franceschini N, Bennett WM. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311.
23. Groetzner J, Kaczmarek I, Landwehr P, et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004; 25: 333.
24. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568.
25. Lobach NE, Pollock-Barziv SM, West LJ, Dipchand AI. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant 2005; 24: 184.
26. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1.
27. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 5; 16: 46.
28. Daniel C, Pippin J, Shankland SJ, Hugo C. The rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1. Lab Invest 2004; 84: 588.
29. Trosch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004; 52: 163.
30. Moloney ED, O'Mahony U, Kirwan M, et al. Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment. Transplant Proc 2004; 36: 1547.
31. Zakliczynski M, Nozynski J, Zakliczynska H, et al. Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc 2003; 35: 2331.
32. Lam P, Yoshida A, Brown K, et al. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci 2004; 49: 1029.
33. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126.
34. Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198.
35. Sennesael JJ, Bosmans JL, Bogers JP, et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005; 80: 1578.
36. Ruiz JC, Diekmann F, Campistol JM, et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study. Transplant Proc 2005; 37: 3833.
37. Weber S, Tonshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: Clinical and genetic aspects. Transplantation 2005; 80: S128.
38. Blume C, Heise G, Hess A, et al. Different effect of cyclosporine A and mycophenolate mofetil on passive Heymann nephritis in the rat. Nephron Exp Nephrol 2005; 100: e104.
39. Dervaux T, Caillard S, Meyer C, et al. Is sirolimus responsible for proteinuria? Transplant Proc 2005; 37: 2828.
40. Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006; 6: 429.
41. Stamp L, Searle M, O'Donnell J, Chapman P. Gout in solid organ transplantation: A challenging clinical problem. Drugs 2005; 65: 2593.
42. Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout after kidney transplantation: Incidence, risk factors and implications. Transplantation 2005; 80: 1383.
43. Marcen R, Gallego N, Orofino L, et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 1995; 70: 307.
44. Laine J, Holmberg C. Mechanisms of hyperuricemia in cyclosporinetreated renal transplanted children. Nephron 1996; 74: 318.
45. Zurcher RM, Bock HA, Thiel G. Hyperuricemia in cyclosporin-treated patients: GFR-related effect. Nephrol Dial Transplant 1996; 11: 153.
46. Hansen JM, Fogh-Andersen N, Leyssac PP, Strandgaard S. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Nephron 1998; 80: 450.
47. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991.
48. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170.
49. Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35: 143S.
50. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model. Am J Transplant 2002; 2: 551.
51. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555.
52. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004; 23: 632.